Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To conduct a phase 1 dose escalation trial in patients with advanced solid tumors and evaluate the rational combination of TORC 1/2 inhibitor TAK-228 and Aurora A kinase inhibitor alisertib

Next Previous
Search
Trial Profile

To conduct a phase 1 dose escalation trial in patients with advanced solid tumors and evaluate the rational combination of TORC 1/2 inhibitor TAK-228 and Aurora A kinase inhibitor alisertib

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 May 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alisertib (Primary) ; Sapanisertib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions

    • Most Recent Events

    • 26 May 2020 New trial record
    • 15 May 2020 Results assessing the rational combination of TORC 1/2 inhibitor TAK-228 and Aurora A kinase inhibitor alisertib in preclinical models of triple-negative breast cancer (TNBC), and to conduct a phase 1 dose escalation trial in patients with advanced solid tumors published in the Clinical Cancer Research

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top